

www.cogstate.com

CogState provides...

Technology solutions for the assessment of thinking in humans



Business Segments

Clinical drug trials


- Customers are pharma / biotech companies
- Quantify the effects of drugs on human subjects in clinical trials

Sport

- Customers are athletes, parents, schools, doctors, sports teams or sporting associations
- Quick and efficient web based tool that can assist doctors in facilitating the safe return of athletes to the playing field and/or classroom following a concussion

Dementia screening


- An efficient and non-invasive tool to identify cognitive decline associated with dementia
- R&D activity currently in Alzheimer's disease,
 Mild Cognitive Dementia and HIV Dementia




Financial results - 30 June 2010

- 2nd consecutive profit result, with Net Profit After Tax A\$1.6 million
- Operating profit A\$0.5 million impacted by development costs :
 - A new product (NTB) that will deliver sales growth in Alzheimer's disease studies
 - Resources devoted to analysis of Sport opportunities...Axon Sports
 - Web-based training system that will delivering gross margin improvement


CogState Sales Revenue and Profitability, by Financial Year






Sales growth impacted by A\$ strength

- Sales contracts and invoices denominated in US\$
- Measured in US\$, sales grew by 35% in 2010
- Expect even greater currency impact for FY2011



Sales contracts - 30 June 2010

23% growth in sales contracts, measured in US\$



Commercial opportunity

CogState's core business has delivered consecutive profit results

We know that we have technology that is reliably sensitive to changes in thinking

The opportunity is to use that same technology to answer questions about people's thinking in the broader community...to market and deliver products that allow people to make health decisions

Opportunities in core business - clinical trials

We've added to our product line (NTB) and developed systems to support the use of paper and pencil tests and

... we can further enhance our product line, using those same systems to support additional tests and provide a full service to our customers

We've developed systems to improve margins (web-based training system) and

... we are working on automated real time data integrity and data management systems that will identify errors that occur at site and seek to eliminate systematic errors from data





Sport

www.axonsports.com




Axon Sports, a joint venture between CogState and Quixote Investment LLC, was launched in the US in August 2010

Partners providing sports product marketing and distribution expertise

Total US market estimated at US\$150 – US\$275 million p.a.

Extensive presentation of Axon Sports (market size, business model, management expertise) available at: http://www.cogstate.com/recentnews


Concussion in sport is a serious issue



Research & Development Activities

Early detection of Alzheimer's disease

- Cognitive decline on the CogState memory test predicts a 3 fold increased risk of early AD
- Our studies in 50+ year olds have shown 53% with memory decline have excess amyloid on PET scans vs 18% without memory decline
- Excess amyloid predicts very high risk of progression to AD in the next 10-20 years
- Provides a model for non-invasive and cost effective early detection of AD in the community
- Additional clinical validation studies are being performed in collaboration with major academic studies:
 - The CSIRO Australian Imaging Biomarker & Lifestyle (AIBL) study
 - Alzheimer's Aust (Vic) Community screening study
 - Pharma funded AIBL/Rate of Change Study



Research & Development Activities

Platforms for large longitudinal studies

- 1000's of study participants living in the community
- Can't use traditional methods of cognitive assessment
- Online testing for cost-effective and remote screening to detect those requiring detailed supervised on-site testing
- Currently used in Brain Mind Research Institute CREDO study of mood training in NSW (Uni of Sydney, ANU)
- Planned use in University of Minnesota NUN study...


HIV Dementia Screening

- Cost-effective cognitive surveillance for decline in Combined Retroviral Therapy treated HIV patients
- Clinic studies underway

Multiple sclerosis

 Cost-effective monitoring of cognition in patients on therapy & detection of early CNS viral reactivation (PML).





MRI of viral infection

Conclusions

- Significant upside for CogState as we seek to expand our core business
 - Focus on Alzheimer's disease
 - Use technological data integrity tools to increase use in other disease indications
 - Look to build alliances in pharma industry (as we did in the Sport market)
- We have partnered well in the Sport market and we believe that Axon Sports will demonstrate success over the next 24 months
 - Major distribution agreement under negotiation currently
 - Expect the market to continue to grow
 - Legislative changes and media attention will drive uptake
- Significant R&D activity in the broader areas of screening



First half forecast – FY2011

- All revenues are expected to come from clinical trials
 - Axon Sports will be equity accounted below the Operating Profit line
 - Screening will not generate any significant revenue in H1
- H1 sales contracts are expected to be approx equal to the previous corresponding half (in US\$)
- However H1 revenue expected to be less than the previous corresponding half
 - Approx A\$3.5-\$4 million (FY10: H1 A\$5.1m, H2 A\$4.4m)
 - Approx 50% difference due to currency effect
 - Revenue recognition impacted by timing of contracts (more contracts in the 2nd quarter)
- Expect loss from operations of approx A\$1m for H1
- Below the line loss of A\$0.6m for H1, including loss from Axon Sports JV and contract termination fees
- Total H1 loss forecast A\$1.6m
- Of which half (A\$0.8m) is due to the strengthening A\$
- Clinical Trial sales prospects now strong after slow start to the financial year
 - Sales contracts always lead revenue recognition by 3-6 months
 - H2 revenue expected to improve on H1, even at current A\$ rates

